Library / regulatory-reference
Switzerland: Swissmedic
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
Swissmedic is Switzerland's national agency for the authorization and supervision of medicines and medical devices. It is an independent public-law institution linked to the federal health ministry, and its decisions cover one of the world's most research-intensive pharmaceutical markets - home to several of the largest global drug companies.
Switzerland is not a member of the European Union or the European Economic Area, so it runs its own fully independent authorization system even though its technical requirements closely track European standards.
How products enter the market
Medicines require a national marketing authorization based on quality, safety, and efficacy documentation aligned with international (ICH) standards. Switzerland also operates simplified authorization routes for products already approved by trusted reference authorities, and it participates in the Access Consortium - a work-sharing partnership with the regulators of Australia, Canada, Singapore, and the United Kingdom that conducts joint reviews.
Medical devices follow a risk-class system aligned with the European framework (classes I, IIa, IIb, III, with the MDR/IVDR rule structure), and since the mutual recognition agreement with the EU lapsed for devices, Switzerland requires its own Swiss conformity marking, authorized representatives for foreign manufacturers, and registration in the Swiss device database.
Speeding access
Swissmedic offers fast-track and priority-review procedures for products addressing serious diseases and high unmet need, and it can authorize temporary use of not-yet-authorized medicines for individual patients with life-threatening conditions on a physician's request.
A distinctive feature is temporary authorization with rolling data submission, allowing promising products to reach patients while evidence is still being completed, with obligations to deliver the remaining data.
Using this profile
Administrators and researchers should treat Swissmedic's authorization database and public assessment reports (SwissPARs) as the primary record of product status; the agency publishes unusually transparent assessment documentation, largely in German, French, and English.
For cross-country comparison: Switzerland is a useful case of a small, high-capacity authority that combines a fully sovereign system with deep reliance mechanisms - Access Consortium joint reviews and reference-authority routes - rather than duplicating every assessment. The authority portal listed in this profile's internal reference record is the primary source for current rules.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies procedures and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.